#United States #New York #Investor Recovery #Telix Pharmaceuticals #TLX

Class Action Lawsuit Filed Against Telix Pharmaceuticals Ltd.

On December 26, 2025, Levi & Korsinsky, LLP announced that a class action lawsuit has been initiated against Telix Pharmaceuticals Ltd. (NASDAQ: TLX). This legal action seeks to recover losses for investors who were affected by alleged securities fraud during a specified time period from February 21, 2025, to August 28, 2025.

Understanding the Class Action

A class action lawsuit allows a group of investors, who share similar claims, to combine their cases into a single lawsuit. This can make it easier for investors to seek justice against more powerful companies. In this situation, the lawsuit is centered around accusations that Telix Pharmaceuticals misled its investors, resulting in significant financial losses. Investors believe that the company's management either made false statements or concealed important information relevant to the company's business and prospects.

Allegations Against Telix Pharmaceuticals

The filed complaint alleges several key points:
1. Overstatement of Progress: The lawsuit claims that Telix's management greatly exaggerated the development of its prostate cancer treatments, leading to inflated stock values based on these misrepresentations.
2. Supply Chain Misrepresentation: It is also alleged that the quality of Telix's supply chain and partnerships was overstated, creating a false sense of security for investors regarding the company's operational capabilities.
3. Materially False Statements: Overall, the lawsuit asserts that the defendants' comments regarding Telix’s operations and prospects were misleading and lacked any reasonable basis, influencing investors’ decisions based on faulty information.

How Can Affected Investors Respond?

For investors who suffered losses during the specified time frame, there is a pressing opportunity to join the class action. Those wanting to participate must act quickly; they have until January 9, 2026, to request that the Court appoint them as lead plaintiffs. However, it’s important to note that participation in the recovery process does not require someone to be a lead plaintiff.

Opportunity Without Financial Risk

Levi & Korsinsky emphasizes that if you are a class member, you could be eligible for compensation without any need for out-of-pocket expenses. This means that individuals can participate in the lawsuit without paying legal fees or covering litigation costs initially.

The Track Record of Levi & Korsinsky

Levi & Korsinsky has a long-standing reputation in the field of securities litigation, having secured hundreds of millions of dollars for aggrieved shareholders over the past two decades. The firm’s team, comprised of over 70 skilled professionals, is dedicated to representing investors in complex legal battles, which has earned them a consistent spot in ISS Securities Class Action Services' Top 50 Report for seven years in a row.

If you believe you were misled by Telix Pharmaceuticals and incurred losses due to alleged fraudulent activities, now is the time to seek justice and potentially recover your investments.

For more information or to discuss your case, you can contact attorneys at Levi & Korsinsky via email at email protected] or by phone at (212) 363-7500. Investors can also find additional details about the case and how to participate through their [official website.

• ---

Contact Information:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
Tel: (212) 363-7500
Fax: (212) 363-7171
Website: www.zlk.com